論文・総説 - 工藤　篤

21. Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, Kobayashi N, Utsunomiya D, Hata M, Ichikawa Y, Tanabe M, Hosono M, Kinuya S. Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci. 2022.04; 29 (4): 487-499. ( PubMed, DOI )

22. Kato T, Kudo A, Kinowaki Y, Ishikawa Y, Watanabe S, Akahoshi K, Ogawa K, Ono H, Ban D, Tanaka S, Tanabe M. A novel classification of portal venous tumor invasion to predict residual tumor status after surgery in patients with pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol. 2022.04; 148 (4): 931-941. ( PubMed, DOI )

23. Kudo Atsushi, Tateishi Ukihide, Yoshimura Ryoichi, Tsuchiya Junichi, Yokoyama Kota, Takano Shoko, Kobayashi Noritoshi, Utsunomiya Daisuke, Hata Masaharu, Ichikawa Yasushi, Tanabe Minoru, Hosono Makoto, Kinuya Seigo. 神経内分泌腫瘍に対する177Lu-DOTATATEを用いたペプチド受容体放射性核種療法後の安全性と反応性に関する日本での第1/2相前向き試験(Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial) Journal of Hepato-Biliary-Pancreatic Sciences. 2022.04; 29 (4): 487-499. ( 医中誌 )

24. Maekawa A, Kudo A, Kishino M, Murase Y, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Tanaka S, Kinowaki Y, Tanabe M. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy. J Cancer Res Clin Oncol. 2022.03; 148 (3): 697-706. ( PubMed, DOI )

25. Watanabe H, Fujishima F, Komoto I, Imamura M, Hijioka S, Hara K, Yatabe Y, Kudo A, Masui T, Tsuchikawa T, Sakamoto K, Shiga H, Nakamura T, Nakaya N, Motoi F, Unno M, Sasano H. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors. Cancers (Basel). 2022.02; 14 (3): 775. ( PubMed, DOI )

26. Matsudera S, Kano Y, Aoyagi Y, Tohyama K, Takahashi K, Kumaki Y, Mitsumura T, Kimura K, Onishi I, Takemoto A, Ban D, Ono H, Kudo A, Oshima N, Ogino K, Watanabe S, Tani Y, Yamaguchi T, Nakajima M, Morita S, Yamaguchi S, Takagi M, Ishikawa T, Nakagawa T, Okamoto K, Uetake H, Tanabe M, Miyake S, Tsuchioka T, Kojima K, Ikeda S. A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Ann Surg Oncol. 2021.12; 28 (13): 8497-8505. ( PubMed, DOI )

27. Murase Y, Ono H, Ogawa K, Yoshioka R, Ishikawa Y, Ueda H, Akahoshi K, Ban D, Kudo A, Tanaka S, Tanabe M. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers. Cancer Science. 2021.11; 112 (11): 4641-4654. ( PubMed, DOI )

28. Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol. 2021.11; 56 (11): 1033-1044. ( PubMed, DOI )

29. Murase Yoshiki, Ono Hiroaki, Ogawa Kosuke, Yoshioka Risa, Ishikawa Yoshiya, Ueda Hiroki, Akahoshi Keiichi, Ban Daisuke, Kudo Atsushi, Tanaka Shinji, Tanabe Minoru. 阻害剤ライブラリースクリーニングにより、膵臓癌の新たな治療薬候補としてイスピネシブが同定された(Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers) Cancer Science. 2021.11; 112 (11): 4641-4654. ( 医中誌 )

30. Ito Tetsuhide, Masui Toshihiko, Komoto Izumi, Doi Ryuichiro, Osamura Robert Y., Sakurai Akihiro, Ikeda Masafumi, Takano Koji, Igarashi Hisato, Shimatsu Akira, Nakamura Kazuhiko, Nakamoto Yuji, Hijioka Susumu, Morita Koji, Ishikawa Yuichi, Ohike Nobuyuki, Kasajima Atsuko, Kushima Ryoji, Kojima Motohiro, Sasano Hironobu, Hirano Satoshi, Mizuno Nobumasa, Aoki Taku, Aoki Takeshi, Ohtsuka Takao, Okumura Tomoyuki, Kimura Yasutoshi, Kudo Atsushi, Konishi Tsuyoshi, Matsumoto Ippei, Kobayashi Noritoshi, Fujimori Nao, Honma Yoshitaka, Morizane Chigusa, Uchino Shinya, Horiuchi Kiyomi, Yamasaki Masanori, Matsubayashi Jun, Sato Yuichi, Sekiguchi Masau, Abe Shinichi, Okusaka Takuji, Kida Mitsuhiro, Kimura Wataru, Tanaka Masao, Majima Yoshiyuki, Jensen Robert T., Hirata Koichi, Imamura Masayuki, Uemoto Shinji, Ito Tetsuhide, Guidelines Committee for creating and evaluating the "Clinical practice guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms(GEP-NEN)2019", The Japanese Neuroendocrine Tumor Society(JNETS). 日本神経内分泌腫瘍研究会(JNETS)膵・消化管神経内分泌腫瘍(NEN)診療ガイドライン　診断、治療、および経過観察　梗概(JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis) Journal of Gastroenterology. 2021.11; 56 (11): 1033-1044. ( 医中誌 )

31. Ito T, Fujimori N, Honma Y, Kudo A, Hijioka S, Katsushima S, Kimura Y, Fukutomi A, Hisamatsu S, Nakajima A, Shimatsu A. Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study. Asia Pacific J Clinical Oncology. 2021.10; 17 (5): e153-e161.

32. Murase, Y; Kudo, A; Akahoshi, K; Maekawa, A; Ishikawa, Y; Ueda, H; Ogawa, K; Ono, H; Tanaka, S; Tanabe, M. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms ANNALS OF GASTROENTEROLOGICAL SURGERY. 2021.09; 5 (5): 692-700. ( PubMed, DOI )

33. Murase Yoshiki, Kudo Atsushi, Akahoshi Keiichi, Maekawa Aya, Ishikawa Yoshiya, Ueda Hiroki, Ogawa Kosuke, Ono Hiroaki, Tanaka Shinji, Tanabe Minoru. 進行膵神経内分泌腫瘍患者の生存の改善を目指したスニチニブ投与後切除(Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms) Annals of Gastroenterological Surgery. 2021.09; 5 (5): 692-700. ( 医中誌 )

34. Akasu M, Shimada S, Kabashima A, Akiyama Y, Shimokawa M, Akahoshi K, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Scientific Reports. 2021.08; 11 (1):

35. Matsui S, Ono H, Asano D, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Kudo A, Tanaka S, Tanabe M. Pancreatic metastasis from renal cell carcinoma presenting as gastrointestinal hemorrhage: a case report. Jornal of Surgical Case Reports. 2021.08; 2021 (8):

36. Akasu, M; Shimada, S; Kabashima, A; Akiyama, Y; Shimokawa, M; Akahoshi, K; Kudo, A; Yamaoka, S; Tanabe, M; Tanaka, S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma SCIENTIFIC REPORTS. 2021.08; 11 (1): 16732. ( PubMed, DOI )

37. Matsui, S; Ono, H; Asano, D; Ishikawa, Y; Ueda, H; Akahoshi, K; Ogawa, K; Kudo, A; Tanaka, S; Tanabe, M. Pancreatic metastasis from renal cell carcinoma presenting as gastrointestinal hemorrhage: a case report JOURNAL OF SURGICAL CASE REPORTS. 2021.08; 2021 (8): rjab368. ( PubMed, DOI )

38. Kato T, Ono H, Fujii M, Akahoshi K, Ogura T, Ogawa K, Ban D, Kudo A, Tanaka S, Tanabe M. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. PLoS One. 2021.06; 16 (6): e0252917.

39. Aoki T, Kubota K, Kiritani S, Arita J, Morizane C, Masui T, Kudo A, Komoto I, Hatano E, Ito T, Osamura RY, Unno M, Uemoto S, Kokudo N. Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS). J Hepatobiliary Pancreat Sci. 2021.06; 28 (6): 489-497. ( PubMed, DOI )

40. Kato, T; Ono, H; Fujii, M; Akahoshi, K; Ogura, T; Ogawa, K; Ban, D; Kudo, A; Tanaka, S; Tanabe, M. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells PLOS ONE. 2021.06; 16 (6): e0252917. ( PubMed, DOI )